UK’s CMA Doubles Down On Liothyronine Objections
Following Ruling On Unfair Pricing For Phenytoin In March
The UK’s CMA has reiterated its belief that Advanz Pharma charged excessive and unfair prices for liothyronine in the UK, following a separate ruling that provided detailed guidance on how such matters should be evaluated.
